黃曉平,王曉,董浩,趙小峰,李招發,2,王啟釗,2,許瑞安,2,刁勇,2
1 華僑大學分子藥物學研究所,泉州 362021 2 分子藥物教育部工程研究中心,泉州 362021
重組人kallistatin蛋白在畢赤酵母中的高效表達及生物活性分析
黃曉平1,王曉1,董浩1,趙小峰1,李招發1,2,王啟釗1,2,許瑞安1,2,刁勇1,2
1 華僑大學分子藥物學研究所,泉州 362021 2 分子藥物教育部工程研究中心,泉州 362021
為了研究kallistatin(Kal)的生物活性,本實驗構建了可分泌表達Kal的畢赤酵母菌株。首先通過PCR方法從pAAV-Kal中擴增出Kal cDNA,并克隆至酵母表達載體pPIC9,得到甲醇酵母分泌型表達載體pPIC9-Kal,然后將載體線性化并電擊轉化畢赤酵母GS115(his4),通過MD平板篩選出陽性表達菌株。陽性表達菌株在BMMY培養基(pH 7.0)中29℃培養,經2%甲醇誘導表達96 h,搖瓶表達量可達14 mg/L。表達上清經Phenyl Superose、Heparin Sepharose FF分離純化,目的蛋白純度達到98%,分子量為58 kDa。生物活性實驗顯示,所得到的Kal蛋白具有較好的抗氧化活性,過氧化物酶活性達到(163±4)U/(mg·min),可有效降低H2O2對LX-2細胞的氧化損傷。另外,重組產生的Kal還能抑制HUVEC細胞的增殖。本研究首次成功地利用畢赤酵母表達系統分泌表達了有生物活性的Kal,為繼續開展其抗腫瘤活性奠定了基礎。
kallistatin,畢赤酵母,表達,活性
Abstract:In order to research the bioactivity of kallistatin(Kal), we obtained the recombinant Kal using Pichia pastoris expression system.Kal cDNA was amplified from pAAV-Kal and inserted into pPIC9 vector to generate a recombinant vector of pPIC9-Kal.Then, pPIC9-Kal was linearized and transformed into Pichia pastoris strain GS115(His4)by electroporation.The positive transformants were selected by MD plate and confirmed by PCR.High level of Kal was obtained in BMMY medium(pH 7.0)after 96 hours induction of 29°C and 2% methanol, with the highest yield of 14 mg/L in shake flask culture.Kal protein was purified from the supernatant with Phenyl Superose and Heparin Sepharose FF chromatograph.The recombinant Kal had a molecularweight of 58 kDa with 98% purity, showing by SDS-PAGE.Moreover, it had a high peroxidase activity(163±4)U/(mg·min), which could protect LX-2 cell against oxidation of H2O2.Recombinant Kal also effectively inhibited HUVEC proliferation.In this report,we successfully established the expression system using Pichia pastoris and obtained the bioactive recombinant human Kal.It lays a foundation for its further anti-cancer therapy.
Keywords:kallistatin, Pichia pastoris, expression, activity
Kallistatin(Kal)是由401個氨基酸組成、分子量為58 kDa的內源性蛋白,具有多種生物學活性,如降血壓[1]、舒張血管[2]、促進血管新生內膜的形成[3]、抗炎[4]和抗氧化[5]等。最近的研究表明,Kal具有廣譜的抗腫瘤活性,符合抗腫瘤藥物應具有多靶點和多信號通路阻斷的要求,值得深入開發。其抗血管生成作用與已上市藥物內皮抑素(Endostatin)類似,可以與VEGF和bFGF等生長因子競爭結合硫酸肝素糖蛋白(HSPGs)受體,因此可阻斷這些生長因子引發的血管生成。……